Leah Mattson went to Turkey for a body lift, but was left with disfigurements instead of achieving her dream body.
The FDA has approved Astellas’s zolbetuximab (Vyloy) for HER2-negative, claudin-18.2 (CLDN18.2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. It is the first CLDN18.2 ...